Search results
Results from the WOW.Com Content Network
Five Prime Therapeutics (NASDAQ: FPRX) shares are trading higher on Monday after Wedbush upgraded the company's stock from Neutral to Outperform and raised its price target from $5 to $9.Five ...
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 20.80% and 29.22%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Shares of Five Prime Therapeutics (NASDAQ:FPRX) were unchanged in after-market trading after the company reported Q3 results.Quarterly Results Earnings per share increased 28.16% over the past ...
2021: In March, the company announced it would acquire Five Prime Therapeutics and its lead candidate, bemarituzumab, for $1.9 billion. [93] [94] [95] In the same month, Amgen acquired Rodeo Therapeutics for $720 million. [96] [97] The FDA approved Amgen's Lumakras in May for treatment of patients with KRAS-G12C-mutated non-small cell lung ...
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -21.31% and -41.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for ...
Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
For premium support please call: 800-290-4726 more ways to reach us
A chart created with data from a Microsoft Excel spreadsheet that only saves the chart. To save the chart and spreadsheet save as .XLS. XLC is not supported in Excel 2007 or in any newer versions of Excel. Dialog .xld: Used in older versions of Excel. Archive .xlk: A backup of an Excel Spreadsheet Add-in (DLL) .xll